The Dermatologist caught up with Dr Taylor to get her thoughts on current rosacea treatment and potential future therapies.

FDA Alerts

FDA Alerts
Thursday, January 19, 2017
The FDA recently has approved the topical treatment, oxymetazoline hydrochloride (Rhofade, Allergan plc) cream, for patients with persistent facial erythema associated with rosacea in adults.
FDA Alerts
Monday, May 12, 2014
Mirvaso is the first and only FDA-approved topical treatment for persistent erythema of rosacea. The FDA approved Mirvaso (brimonidine) Topical Gel, 0.33% in August 2013 as the first and only topical treatment indicated for the persistent (non-transient) facial erythema of rosacea in adults age 18 or older. The gel, marketed by Galderma Laboratories, L.P., is an alpha-2 adrenergic agonist that may work by constricting the dilated blood vessels to reduce the redness of rosacea. 

News

News
Thursday, October 18, 2018
Findings from a recent study demonstrated a potential association between coffee intake and the risk of rosacea.
News
Tuesday, April 24, 2018
Researchers investigated the efficacy of a pulsed dye laser with a novel treatment beam among participants with erythemato‐telangiectatic rosacea. For study results, read more.
News
Monday, March 5, 2018
In a recent study, researchers investigated the safety and efficacy of a topical cream compared with vehicle for reducing erythema among patients with rosacea.
News
Tuesday, December 5, 2017
In a recent study, researchers examined the risk of rosacea in women with obesity.

Research in Review

Research in Review
Tuesday, October 30, 2018
The Dermatologist caught up with Dr Taylor to get her thoughts on current rosacea treatment and potential future therapies.
Research in Review
Wednesday, August 29, 2018
Despite the fact that dermatologists’ knowledge of rosacea has evolved, they still follow treatment protocols aligned with the now outdated subtypes.
Research in Review
Thursday, July 5, 2018
The survey offers insights into the emotional, psychological, and societal impact of the condition.
Research in Review
Monday, June 25, 2018
Harvey H. Jay, MD, in private practice in New York, NY, spoke with The Dermatologist about recent advances in the field, the psychosocial impact of rosacea, and how he uses intense pulse light (IPL) in his practice to treat patients with rosacea.